Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
DURHAM, N.C., Dec. 28, 2021 – Bioventus (Nasdaq: BVS) announced that CEO Ken Reali will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 p.m. ET. The presentation will be accessible via a live webcast on the Bioventus investors website, and it will also be archived for later viewing. Bioventus is dedicated to providing innovative, clinically proven products that facilitate active healing and enhance patient recovery.
Bioventus (Nasdaq: BVS) has appointed Dr. Michelle McMurry-Heath to its Board of Directors, effective January 1, 2022. With over 20 years of experience in healthcare and regulatory roles, McMurry-Heath brings valuable insights to the company. Her previous positions include leading regulatory science at Johnson & Johnson and serving at the FDA. Bioventus aims to leverage her expertise in medical innovation and regulatory affairs to advance its offerings in pain treatment and restorative therapies. Company leadership expresses optimism about the strategic guidance she will provide.
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece, enhancing minimally invasive surgery with improved bone removal capabilities. This device, part of the neXus Ultrasonic Surgical Aspirator System, offers surgeons greater control and versatility. The launch is anticipated in 2022, with the system already commercialized in several countries. The BoneScalpel Access is indicated for use across various surgical specialties, indicating a broad application potential.
Bioventus (Nasdaq: BVS) announced a lease agreement to expand its operational and manufacturing space in Memphis, doubling its current area. The new facility, located at 7101 Goodlett Farms Parkway in Cordova, TN, features approximately 90,000 square feet, with 55,000 dedicated to manufacturing. This move is set for early Q3 2022 and will create an additional 40 jobs over five years. The expansion aligns with the company’s strategy for organic growth and vertical integration, enhancing its manufacturing capabilities.
Bioventus (Nasdaq: BVS) announced the departure of Greg Anglum from his role as CFO, effective immediately. Anglum will remain until a successor is identified. CEO Ken Reali praised Anglum for his contributions over five years, including during the IPO and recent acquisitions. The company reassures stakeholders that his departure is not due to business performance issues, reaffirming its financial guidance for 2021. Bioventus is actively seeking a new CFO to support its growth strategy.
Bioventus Inc. (Nasdaq: BVS) reported Q3 2021 net sales of $108.9 million, up 26.8% year-over-year, driven by strong commercial execution and acquisitions. The company generated a net loss of $2.3 million, down from net income of $8.0 million in Q3 2020. Adjusted EBITDA was $21.3 million, a decline of 7.7% year-over-year. Bioventus updated its full-year sales guidance to $425-$430 million, reflecting 32% to 34% growth. The company successfully integrated Bioness and completed the acquisition of Misonix, positioning itself for further growth in the healing innovations sector.
Bioventus (Nasdaq: BVS) announced the appointment of Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs. Klugewicz will oversee global regulatory and quality functions, aiming for integration post-Misonix acquisition. She has significant experience, previously serving as COO of Misonix and holding senior positions at Chembio Diagnostic Systems. Her expertise is expected to enhance Bioventus’ growth strategy in pain treatment and surgical solutions. This leadership change aligns with the company's focus on quality and innovation in its product offerings.
Bioventus Inc. (Nasdaq: BVS) has acquired Misonix, Inc., enhancing its position in regenerative medicine and surgical applications. Misonix stockholders can choose $28 in cash or 1.6839 shares of Bioventus stock per share held. This strategic acquisition targets a $15 billion market, aiming for double-digit revenue growth. The integration is expected to broaden Bioventus' commercial reach, leveraging its extensive sales force in areas like spinal surgery and wound treatment. Key leadership from Misonix will join Bioventus' board, indicating a commitment to shared growth.
Bioventus (Nasdaq: BVS) will release its third quarter fiscal year 2021 financial results on November 9, 2021, before market opening. The company will host a conference call at 8:30 a.m. ET to discuss these results and offer a business update. Participants can join by dialing 844-945-2085, with an international dial-in option available. A live webcast will also be accessible on the company's investor relations website and will be archived for future reference until November 9, 2022.
Bioventus (Nasdaq: BVS) has received stockholder approval for its acquisition of Misonix (Nasdaq: MSON), expected to close by October 29, 2021. This merger was initially announced on July 29, 2021, under which Misonix stockholders will receive either 1.6839 shares of Bioventus stock or $28 in cash for each share of Misonix. The deal represents a 25% premium based on Misonix's 30-day VWAP prior to the agreement. Following the merger, Misonix will become a wholly-owned subsidiary of Bioventus, enhancing their global pain treatment and restorative therapy portfolio.